146 related articles for article (PubMed ID: 28739902)
1. Rho-associated kinase is a therapeutic target in neuroblastoma.
Dyberg C; Fransson S; Andonova T; Sveinbjörnsson B; Lännerholm-Palm J; Olsen TK; Forsberg D; Herlenius E; Martinsson T; Brodin B; Kogner P; Johnsen JI; Wickström M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6603-E6612. PubMed ID: 28739902
[TBL] [Abstract][Full Text] [Related]
2. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
3. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
[TBL] [Abstract][Full Text] [Related]
5. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract][Full Text] [Related]
6. INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma.
Chen C; Breslin MB; Lan MS
Oncotarget; 2015 Nov; 6(34):36700-12. PubMed ID: 26456864
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.
Lynch J; Fay J; Meehan M; Bryan K; Watters KM; Murphy DM; Stallings RL
Carcinogenesis; 2012 May; 33(5):976-85. PubMed ID: 22382496
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
10. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
12. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP
Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250
[TBL] [Abstract][Full Text] [Related]
13. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
14. RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma.
Ma W; Sze KM; Chan LK; Lee JM; Wei LL; Wong CM; Lee TK; Wong CC; Ng IO
Oncotarget; 2016 Jul; 7(27):41445-41459. PubMed ID: 27213590
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
16. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
[TBL] [Abstract][Full Text] [Related]
17. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson PJ; Henriksson MA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10258-63. PubMed ID: 23733953
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
[TBL] [Abstract][Full Text] [Related]
19. Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.
Fife CM; Sagnella SM; Teo WS; Po'uha ST; Byrne FL; Yeap YY; Ng DC; Davis TP; McCarroll JA; Kavallaris M
Oncogene; 2017 Jan; 36(4):501-511. PubMed ID: 27321182
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
